Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 3
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Characterization of respiratory bacterial co-infection and assessment of empirical antibiotic treatment in patients with COVID-19 at hospital admission

  • Antuori Torres, Adrián|||0000-0002-2782-3125
  • Giménez Pérez, Montserrat|||0000-0001-8841-810X
  • Linares, Georgina
  • Cardona, Pere-Joan|||0000-0001-5623-7873
Accurate characterization of respiratory bacterial co-infection is critical for guiding empirical antibiotic treatment for hospitalised patients with coronavirus disease 2019 (COVID-19). We retrospectively assessed the clinical and analytical predictors of respiratory bacterial co-infection and described the empirical use of antibiotics in COVID-19 hospitalised patients. Respiratory bacterial co-infection was documented in 6.9% (80/1157) of the patients. The predominant bacteria isolates were Haemophilus influenzae, followed by Streptococcus pneumoniae and Pseudomonas aeruginosa. Respiratory bacterial co-infection was associated with having had a positive culture for a respiratory pathogen in the last year (OR = 25.89), dyslipidaemia (OR = 2.52), heart failure (OR = 7.68), ferritin levels < 402 ng/mL (OR = 2.28), leukocyte count.
Dipòsit Digital de Documents de la UAB
Publicación Artículo de revisión (ReviewArticle)

Drosophila melanogaster experimental model to test new antimicrobials, a methodological approach

  • Vidal, Maria
  • Arch Sisquella, Marta|||0000-0002-2120-1667
  • Fuentes, Esther|||0000-0002-6151-8204
  • Cardona, Pere-Joan|||0000-0001-5623-7873
Given the increasing concern about antimicrobial resistance among the microorganisms that cause infections in our society, there is an urgent need for new drug discovery. Currently, this process involves testing many low-quality compounds, resulting from the in vivo testing, on mammal models, which not only wastes time, resources, and money, but also raises ethical questions. In this review, we have discussed the potential of D. melanogaster as an intermediary experimental model in this drug discovery timeline. We have tackled the topic from a methodological perspective, providing recommendations regarding the range of drug concentrations to test based on the mechanism of action of each compound; how to treat D. melanogaster, how to monitor that treatment, and what parameters we should consider when designing a drug screening protocol to maximize the study's benefits. We also discuss the necessary improvements needed to establish the D. melanogaster model of infection as a standard technique in the drug screening process. Overall, D. melanogaster has been demonstrated to be a manageable model for studying broad-spectrum infection treatment. It allows us to obtain valuable information in a cost-effective manner, which can improve the drug screening process and provide insights into our current major concern. This approach is also in line with the 3R policy in biomedical research, in particular on the replacement and reduce the use of vertebrates in preclinical development.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Mycobacterium manresensis induces trained immunity in vitro

  • Homdedeu, Miquel de|||0000-0002-2865-1740
  • Sanchez-Moral, Lidia|||0000-0002-3795-8015
  • Violán, Concepció|||0000-0003-3309-5360
  • Ràfols, Neus
  • Ouchi, Dan|||0000-0002-8630-152X
  • Martín, Berta
  • Peinado, Miguel A.
  • Rodriguez-Cortes, Alheli|||0000-0003-3617-0119
  • Arch Sisquella, Marta|||0000-0002-2120-1667
  • Perez-Zsolt, Daniel|||0000-0003-4192-7622
  • Muñoz-Basagoiti, Jordana|||0000-0002-0384-5928
  • Izquierdo Useros, Nuria|||0000-0002-1039-1821
  • Salvador, Betlem
  • Matllo, Joan
  • López-Serrano, Sergi|||0000-0002-0968-7713
  • Segalés Coma, Joaquim|||0000-0002-1539-7261
  • Vilaplana Massaguer, Cristina|||0000-0002-2808-7270
  • Torán-Monserrat, Pere|||0000-0002-9865-7427
  • Morros, Rosa|||0000-0001-6752-8748
  • Monfà, Ramon|||0000-0002-1324-3971
  • Sarrias, Maria-Rosa|||0000-0001-6929-8069
  • Cardona, Pere-Joan|||0000-0001-5623-7873
The COVID-19 pandemic posed a global health crisis, with new severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants weakening vaccine-driven protection. Trained immunity could help tackle COVID-19 disease. Our objective was to analyze whether heat-killed Mycobacterium manresensis (hkMm), an environmental mycobacterium, induces trained immunity and confers protection against SARS-CoV-2 infection. To this end, THP-1 cells and primary monocytes were trained with hkMm. The increased secretion of tumor necrosis factor alpha (TNF-α), interleukin (IL)-6, IL-1β, and IL-10, metabolic activity, and changes in epigenetic marks suggested hkMm-induced trained immunity in vitro. Healthcare workers at risk of SARS-CoV-2 infection were enrolled into the MANRECOVID19 clinical trial (NCT04452773) and were administered Nyaditum resae (NR, containing hkMm) or placebo. No significant differences in monocyte inflammatory responses or the incidence of SARS-CoV-2 infection were found between the groups, although NR modified the profile of circulating immune cell populations. Our results show that M. manresensis induces trained immunity in vitro but not in vivo when orally administered as NR daily for 14 days. Biological sciences; Molecular biology; Immunology; Microbiology.